All Clinical Trials

Clinical Trial NCT05678959

A three-year, multi-center, double-blind, extension study to evaluate the long-term safety and efficacy of ligelizumab in patients who completed ligelizumab’s Phase III studies in food allergy

  • ClinicalTrials.gov ID: NCT05678959
  • Recruiting participants (Starts Jun. 30, 2023)
  • Not accepting healthy volunteers
  • UTSW Principal Investigator: JOHN ANDREW BIRD

objective

To evaluate the long-term safety and tolerability of ligelizumab in participants with food allergy

If you are interested in this clinical trial, please contact Melissa Zamudio on the Children’s Health Research Team.Call 214-456-5711Email